Investment
Features
FeesSafety
Academy
More
Pluang+

Compare Brigit Biofarmaka Teknologi Tbk. (OBAT) vs Reksa Dana Premier ETF Indonesia Financial (XIIF) Price & Performance

Brigit Biofarmaka Teknologi Tbk.Trade
Reksa Dana Premier ETF Indonesia FinancialTrade

Price performance (Past 24H)

Key statistics

Brigit Biofarmaka Teknologi Tbk. vs Reksa Dana Premier ETF Indonesia Financial — how do they compare? Brigit Biofarmaka Teknologi Tbk. trades at Rp236 (market cap 164.65B, 62.5K 24h volume), while Reksa Dana Premier ETF Indonesia Financial trades at Rp414 (market cap 24.64B, 1.1K 24h volume). The key difference: Brigit Biofarmaka Teknologi Tbk. is far larger — about 6.7× Reksa Dana Premier ETF Indonesia Financial's market cap, and Brigit Biofarmaka Teknologi Tbk. is more actively traded (62.5K versus 1.1K). Which is the better fit depends on your goals.

OBATXIIF
Market Cap
164.65B24.64B
Volume
62.5K1.1K
Lot
62511
Turnover
15.03M455.4K
Average Price
240.55414
Value
15.03M455.4K
Indicative Equilibrium Price
238
Indicative Equilibrium Volume
100

Returns comparison

Trailing returns across standard periods

Top news

Latest headlines on both assets

OBAT
View details

About Brigit Biofarmaka Teknologi Tbk.

PT. Brigit Biofarmaka Teknologi Tbk. (the Company) was established based on Notarial Deed No. 103 dated December 14, 2015 of Yoerista Arya Megasari, S.H., M.Kn., Notary in Sukoharjo. The company starts production commercially in 2018.

Read more on OBAT

About Reksa Dana Premier ETF Indonesia Financial

Read more on XIIF